Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Multiple Myeloma (MM)”

151 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 151 results

Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Testing effectiveness (Phase 2)Study completedNCT02206425
What this trial is testing

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Oncotherapeutics 45
Testing effectiveness (Phase 2)Looking for participantsNCT05594797
What this trial is testing

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Who this might be right for
Multiple Myeloma
Hrain Biotechnology Co., Ltd. 100
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Early research (Phase 1)UnknownNCT05052970
What this trial is testing

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

Who this might be right for
Relapsed or Refractory Multiple Myeloma
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. 60
Early research (Phase 1)Ended earlyNCT04895410
What this trial is testing

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Who this might be right for
Multiple Myeloma
AbbVie 8
Early research (Phase 1)Study completedNCT00258245
What this trial is testing

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Barbara Ann Karmanos Cancer Institute 5
Early research (Phase 1)Looking for participantsNCT07333430
What this trial is testing

Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma (MM)
Hadassah Medical Organization 60
Early research (Phase 1)Ended earlyNCT02579824
What this trial is testing

Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Myeloma
M.D. Anderson Cancer Center 14
Testing effectiveness (Phase 2)Study completedNCT01526694
What this trial is testing

Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM

Who this might be right for
Multiple Myeloma
Azienda Ospedaliera di Bolzano 30
Early research (Phase 1)UnknownNCT05438394
What this trial is testing

Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM

Who this might be right for
Multiple Myeloma
Peking University People's Hospital 24
Very early researchLooking for participantsNCT06045091
What this trial is testing

To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

Who this might be right for
Multiple MyelomaPlasma Cell Leukemia
Hrain Biotechnology Co., Ltd. 18
Testing effectiveness (Phase 2)Study completedNCT02185820
What this trial is testing

Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)

Who this might be right for
Multiple Myeloma
European Myeloma Network B.V. 57
Testing effectiveness (Phase 2)UnknownNCT00800059
What this trial is testing

Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma

Who this might be right for
Multiple Myeloma
Ottawa Hospital Research Institute 27
Not applicableUnknownNCT04447573
What this trial is testing

Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd. 20
Not applicableStudy completedNCT05673967
What this trial is testing

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed and Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 62
Early research (Phase 1)Study completedNCT01582295
What this trial is testing

XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

Who this might be right for
Multiple Myeloma
Massachusetts General Hospital 4
Testing effectiveness (Phase 2)Looking for participantsNCT06627751
What this trial is testing

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Who this might be right for
Extramedullary Disease in Multiple MyelomaRecurrent Multiple MyelomaRefractory Multiple Myeloma
Roswell Park Cancer Institute 28
Early research (Phase 1)Looking for participantsNCT07409246
What this trial is testing

Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
AbbVie 127
Testing effectiveness (Phase 2)Ended earlyNCT04150965
What this trial is testing

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Who this might be right for
Multiple MyelomaRelapsed Refractory Multiple Myeloma
Multiple Myeloma Research Consortium 14
Load More Results